logo
US dollar in danger after worst half-year since the 1970s... here's how it'll shrink your wallet

US dollar in danger after worst half-year since the 1970s... here's how it'll shrink your wallet

Daily Mail​08-07-2025
America's currency just had its worst half-year performance since the Nixon era.
That could mean higher prices for everyday Americans.
The dollar dropped more than 10 percent against major global currencies from January to June, according to the US Dollar Index.
It's the worst first-half showing since the index began tracking the greenback in 1973. For decades, the dollar has served as the world's financial safe haven.
Economists warn the weaker dollar could keep inflation stubbornly high, even as consumer prices cool in other areas of the economy.
'A depreciation in the US dollar is inflationary,' Ryan Sweet, the chief US economist for Oxford Economics, told Newsweek.
'The depreciation in the dollar increases the risks that tariffs boost consumer prices more than anticipated this summer and into the fall.'
Take, for example, the cost of car parts from best-selling Japanese brands like Toyota, Honda, and Nissan.
When the dollar weakens against the Japanese Yen, it takes more dollars to buy the same part from an overseas supplier.
That can push up Americans' repair bills, parts prices, and insurance. It also increases manufacturing costs in the US, where many factories depend on globally sourced components.
Similar price pressures are showing up in other industries that rely on imports — like food, electronics, and clothing.
Coffee from Colombia, apparel from Vietnam, and even roses from Ecuador — all products that have nearly no US manufacturing — can become more expensive and trickle down to consumers at the checkout line.
Bret Kenwell, US investment analyst at eToro, told DailyMail.com there is a mix of good and bad with the dollar's dip.
'A falling dollar can be a good thing for large multinational companies, as it boosts their earnings in non-dollar currencies,' he said.
'However, importers can struggle as it now takes more dollars to buy the same goods as before. For these reasons, many companies look to hedge their currency exposure — especially in volatile environments.'
While a weaker dollar may help exporters compete abroad, it's also reshaping how everyday investors move the money in their portfolios.
A new survey from trading platform eToro found that 58 percent of American retail investors are adjusting their portfolios in response to the dollar's decline.
More than a quarter are pulling back from US stocks and shifting into gold and cryptocurrency — two assets often viewed as hedges against inflation and currency risk.
Younger investors were especially bullish on gold, the survey found. Trust in the US market is also starting to slip from all-time highs.
The dollar has traditionally been seen as safe haven currency for international investors.
But rising national debt, increased inflation, higher interest rates, a wobbly political landscape, and a focus on US manufacturing has chipped away at its long-term dominance.
Some creditors are even worried the US might not be able to service some of its debts.
But top White House advisors say the dollar's long-term strength has come with tradeoffs for US jobs.
Vice President JD Vance has frequently said that dollar dominance has had the reverse impact on countries that want to buy goods built in the US.
A Ford F-150 built in Michigan, for instance, costs significantly more for a customer in Japan than for one in the States.
'If you want to employ a lot of people in manufacturing, you need to make it easier for us to export and not just import what we need,' Vance told Politico.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Beach City abandons 10,000 homes for F1-style race track development
Beach City abandons 10,000 homes for F1-style race track development

Daily Mail​

time21 minutes ago

  • Daily Mail​

Beach City abandons 10,000 homes for F1-style race track development

Locals in a popular New Jersey beach city are enraged after it ditched plans to build 10,000 new homes for a 'dumb' and 'desperate' $3.4 billion F1-style racetrack. Atlantic City government officials have moved forward with the redevelopment of Bader Field, a shuttered airport about an hour outside of Philadelphia, after plans for the new racetrack were officially approved on July 16. The idea to take over the abandoned city-owned airport, which shut down in 2006, first started in 2022 when Bart Blatstein, the CEO of Tower Investments, Inc. and owner of Showboat Atlantic City, said his company and Atlantic City would collaborate to create a massive residential community. The proposed $3 billion development, dubbed 'Casa Mar,' was set to be built on 140 acres with 10,000 residential units, 20 acres of trails, amenities and parks and 400,000 square-feet of retail and office space - but that plan has since been wiped. Instead, a 2.5-mile racetrack, headed by real estate development company Deem Enterprises, will take its place. The massive raceway, said to be a 'game changer' by Atlantic City Mayor Marty Small Sr. (pictured), is expected to take six to nine years to complete. It will be surrounded by retail businesses and condominiums in the community that is home to beaches, a bustling boardwalk and casinos. 'We're more confident than ever that we have the funds, Small Sr., an Atlantic City native who has been in office since 2019, told NJ Advance Media. [DEEM] has been vetted, and just getting a $3.4-plus billion project on the ratable base is a complete game changer.' While the mayor, who was embroiled in a child abuse scandal involving his wife and daughter last year, and other government officials are thrilled about the new plan, Atlantic City locals are not happy with it. 'Atlantic City leadership is so desperate that they will support any development offer no matter how stupid it is,' a Facebook user wrote. Another said: 'What a joke! Want to really do something with the land? Dig canals and sell off lots and watch the ratepayers flood in!' 'Building that into a racetrack has to be the dumbest idea in the world,' someone else posted. Blatstein told the outlet three years ago that he saw room for growth in the beach city after realizing that other Garden State beach towns have booming populations compared to Atlantic City. 'So what really is needed here is a new plan, a new way of living, a new opportunity for people to come to Atlantic City,' Blatstein said. DEEM Enterprises, a Los Angeles and Atlantic City-based company, first announced the proposal in February of that year. The company has a tentative deal with the city to sell the vacant airfield for $100 million in exchange the real estate developer would donate $15 million for a community center. 'We don't have a recreation center of our town,' Small Sr. explained. 'We use the schools and different things like that.' Daily Mail contacted Mayor Small Sr. and DEEM Enterprises for comment.

Weight-loss jab Wegovy sees another prescription boost after ban on copycats
Weight-loss jab Wegovy sees another prescription boost after ban on copycats

The Independent

time23 minutes ago

  • The Independent

Weight-loss jab Wegovy sees another prescription boost after ban on copycats

Novo Nordisk's weight loss drug, Wegovy, is experiencing a surge in new prescriptions following a US ban on its copycat versions, though analysts caution that more substantial growth is needed to reassure investors. Since the US Food and Drug Administration (FDA) implemented a ban on 'compounded' versions of Wegovy on 22 May, new prescriptions for the drug have risen by approximately 33 per cent. This culminated in 181,200 new prescriptions in the week ending 18 July, according to IQVIA data shared with Reuters by industry analysts. The overall increase in Wegovy prescriptions is also narrowing the market lead held by Eli Lilly and Co's rival drug, Zepbound. While Zepbound prescriptions outpaced Wegovy by nearly 175,000 in the US during the week ending 23 May, this gap had reduced to around 133,000 by 18 July. Early signs of a shift come at a critical juncture for Novo. After Wegovy's initial stunning success, investor confidence was rattled when Zepbound and compounders started to slow the drug's growth. And then in May, the Danish company cut its full-year sales and earnings forecasts and announced the surprise exit of Chief Executive Lars Fruergaard Jorgensen, citing market challenges and a stock price nearly 60% below its 2024 peak. Jorgensen said at the time he expected the FDA compounding ban to lift sales in the second half of this year. Investors are keen to hear whether that is still likely when the company reports quarterly earnings on August 6. That leaves the drugmaker in what Barclays analyst Emily Field called a "show me" phase - no longer buoyed by optimism about a turnaround but under pressure to deliver. She has an "overweight" rating on Novo's shares. "We thought this trajectory change (in new prescriptions) would get the shares moving, but not so far," Berenberg analyst Kerry Holford told Reuters. "I suspect investors are now waiting for the (second quarter) update - will they/won't they trim guidance range? I think they will trim the top." Berenberg has a "hold" rating on Novo. Novo did not respond to a request for comment. Investors and analysts note that the IQVIA prescription data is incomplete, because it does not capture sales of Wegovy through the company's direct-to-consumer platform, NovoCare, launched in March. They estimate the channel is still a small slice of overall Wegovy volume. "We would hope to see strong growth from the NovoCare channel but are cognizant that this may come at initially lower prices" due to discount offers, said Marcus Morris-Eyton, a portfolio manager at Alliance Bernstein, whose fund holds Novo shares. "Sentiment towards Novo Nordisk is currently exceptionally weak, but given low expectations, the low valuation and hopefully accelerating prescription data in (the second half of 2025) we believe the market is underestimating Novo's long term growth potential," he said. Booming sales of Wegovy catapulted Novo to become Europe's most valuable listed company, peaking in June 2024 at about 615 billion euros, after the weekly injection became the first highly-effective obesity treatment approved in the U.S. in 2021. But supply disruptions and gaps in health insurance coverage for Wegovy helped fuel the market for cheaper compounded - or copycat - versions, which are allowed under U.S. law when drugs are in shortage. Investor sentiment on Novo soured after the company lost ground to U.S. rival Eli Lilly, which launched Zepbound in late 2023. Capturing more of the patients who had turned to compounded drugs is key to meeting targets. The FDA determined that Wegovy was no longer in shortage in February, leading to the ban on compounded versions. Novo has rolled out new tactics to bring patients back, including a limited-time discount for one month's supply, and secured better coverage from insurer CVS Health. Analysts at Berenberg and UBS are sceptical these moves will provide enough momentum and expect that Novo will reduce or narrow its full-year guidance ranges, according to research notes. TD Cowen said the outcome was hard to predict due to limited visibility on NovoCare. Bank of America and Guggenheim said they did not expect another guidance cut and Barclays said it was unlikely. ($1 = 0.8513 euros)

Musk hails $16.5bn Samsung deal to supply Tesla with AI chips
Musk hails $16.5bn Samsung deal to supply Tesla with AI chips

The Guardian

time24 minutes ago

  • The Guardian

Musk hails $16.5bn Samsung deal to supply Tesla with AI chips

Samsung has agreed a $16.5bn (£12.3bn) deal to manufacture artificial intelligence chips for Tesla, in a move hailed by Elon Musk on Monday. The South Korean tech company announced the contract with an unnamed client in a regulatory filing, with Tesla's chief executive giving further details on his social media platform, X. Musk wrote that Samsung would produce Tesla's next-generation A16 chips at a new plant in Texas. 'The strategic importance of this is hard to overstate,' he wrote. In December, the Biden administration announced $4.75bn in funding for Samsung's semiconductor manufacturing facilities in Texas under the Chips Act, legislation aimed at making the US more self-sufficient in chip manufacturing. At the time, the then US commerce secretary, Gina Raimondo, said the funding would ensure the country had a 'steady stream' of chips essential to AI and national security. In a post of X on Monday, Musk said Samsung had agree to allow Tesla to 'assist in maximising manufacturing efficiency' and that he would 'walk the [manufacturing] line personally to accelerate the pace of progress'. He added that the Samsung plant in Taylor, outside Austin, Texas, was 'conveniently located not far from my house'. The deal will help re-energise a project faced long delays amid Samsung's difficulties in retaining and attracting big clients. Ryu Young-ho, a senior analyst at Seoul-based NH Investment & Securities, said the Taylor plant 'so far had virtually no customers', making the deal 'quite meaningful'. In October, Reuters reported that Samsung had postponed taking deliveries of chipmaking equipment from ASML, a Dutch manufacturer, for the Texas site as it had not yet won any significant customers for the project. It has already delayed the plant's operational start to 2026. Samsung makes Tesla's AI4 chips, which power the carmaker's full self-driving driver assistant system. Taiwan's TSMC is slated to make the AI5 chips for Tesla, initially in Taiwan and then Arizona, Musk has said. Sign up to Business Today Get set for the working day – we'll point you to all the business news and analysis you need every morning after newsletter promotion The regulatory filing by Samsung announcing the chip supply agreement did not name the client, saying the customer had requested confidentiality about the details of the deal, which will run through the end of 2033. Samsung has been approached for comment. Reuters contributed to this article.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store